ArticleMolecular and clinical oncology2026
TTF-1 expression is associated with survival in patients with non-squamous non-small cell lung cancer treated with immune checkpoint inhibitor therapy.
Article in Molecular and clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Survival outcomes in TTF-1 negative non-squamous non-small cell lung cancer (H-LINK 001).Discover oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thyroid transcription factor-1 (TTF-1) expression has been associated with the prognosis of patients with non-small cell lung cancer treated with immune checkpoint inhibitor (ICI) therapy; however, it has also been suggested that there is no such link. The present study analyzed the association of TTF-1 expression, evaluated using a cocktail antibody (TTF-1/napsin A; clone, SPT24/TMU-Ad02), with survival after the initiation of ICI therapy in patients with EGFR/ALK wild-type non-squamous non-small cell lung cancer receiving first-line treatment with ICI monotherapy or chemoimmunotherapy. A total of 49 patients were enrolled to the present study. Multivariate analysis using the Cox proportional hazard model showed that TTF-1 expression was associated with progression-free survival (PFS) after the initiation of treatment with ICI monotherapy or chemoimmunotherapy (hazard ratio: 0.18, 95% confidence interval: 0.06-0.54). Subset analysis showed that the TTF-1-positive group exhibited significantly longer PFS than the negative group in both the ICI monotherapy (median PFS, 17.6 months vs. 2.9 months, P<0.001, log-rank test) and chemoimmunotherapy (median PFS, 10.4 months vs. 5.2 months, P=0.021, log-rank test) groups. In conclusion, the current study observed an association between TTF-1 expression evaluated using a cocktail antibody and the effectiveness of treatment with ICI monotherapy or chemoimmunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.